---
title: "IBRX.US (IBRX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IBRX.US/news.md"
symbol: "IBRX.US"
name: "IBRX.US"
parent: "https://longbridge.com/en/quote/IBRX.US.md"
datetime: "2026-05-20T15:11:47.608Z"
locales:
  - [en](https://longbridge.com/en/quote/IBRX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IBRX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IBRX.US/news.md)
---

# IBRX.US (IBRX.US) — Related News

### [ImmunityBio's Supplemental Biologics License Application for Anktiva Accepted by FDA](https://longbridge.com/en/news/287040567.md)
*2026-05-20T09:28:00.000Z*
> ImmunityBio's supplemental biologics license application for Anktiva, in combination with Bacillus Calmette-Guerin for b

### [15:47 ETImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit](https://longbridge.com/en/news/286958486.md)
*2026-05-19T19:47:21.000Z*
> Investors who suffered losses in ImmunityBio, Inc. (NASDAQ: IBRX) have the opportunity to lead a securities fraud class 

### [ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 | IBRX Stock News](https://longbridge.com/en/news/286980919.md)
*2026-05-19T16:30:26.000Z*
> ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive B

### [ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026 | IBRX Stock News](https://longbridge.com/en/news/286905523.md)
*2026-05-19T03:30:00.000Z*
> ImmunityBio presented data at AUA 2026 showing that NAI+BCG treatment resulted in significantly higher complete response

### [ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG in Supply Pact With Japan BCG Laboratory](https://longbridge.com/en/news/286821171.md)
*2026-05-18T21:23:00.000Z*
> ImmunityBio has secured exclusive U.S. rights to the Tokyo-172 BCG strain through a supply agreement with Japan BCG Labo